Prof Schöffski answers "yes" to the question "Have additional treatment options had a tangible impact on the first-line treatment of mRCC?" and tells us why.

He draws examples from the COMPARZ which showed that pazopanib had better scores than sunitinib for a number of clinically relevant domains and was preferred by patients.

GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.